Market Overview

UPDATE: MLV & Co Downgrades Uroplasty to Hold on Slowing Growth, Competitive Concerns

Related UPI
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement
Stocks Hitting 52-Week Lows

MLV & Co downgraded Uroplasty (NASDAQ: UPI) from Buy to Hold and announced a $3.00 price target.

MLV & Co noted, "Given our expectations for low growth over the next year and the recent approval of two competitive products for OAB from companies with much greater marketing prowess (and budgets) than Uroplasty, we no longer have sufficient visibility to project when the company may reach profitability. Further, we believe lessthan-positive market sentiment and a lack of any meaningful nearterm catalysts will continue to weigh heavily on the shares."

Uroplasty closed at $2.74 on Monday.

Latest Ratings for UPI

Jan 2015Roth CapitalDowngradesBuyNeutral
Jan 2014DoughertyAssumesBuy
May 2013JMP SecuritiesUpgradesMarket PerformMarket Outperform

View More Analyst Ratings for UPI
View the Latest Analyst Ratings

Posted-In: MLV & CoAnalyst Color Downgrades Analyst Ratings


Related Articles (UPI)

View Comments and Join the Discussion!